Roche was in 'ad­vanced' talks to out-li­cense its An­gel­man syn­drome drug, but po­ten­tial part­ner with­drew

Roche is back to square one for find­ing a part­ner to car­ry for­ward its culled An­gel­man syn­drome drug.

Last June, the Swiss phar­ma had start­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.